WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006081388) SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/081388    International Application No.:    PCT/US2006/002871
Publication Date: 03.08.2006 International Filing Date: 25.01.2006
IPC:
A61K 31/4985 (2006.01), C07D 487/04 (2006.01)
Applicants: NEUROGEN CORPORATION [US/US]; 35 Northeast Industrial Road, Branford, CT 06405 (US) (For All Designated States Except US).
CALDWELL, Timothy, M. [US/US]; (US) (For US Only).
CHENARD, Bertrand, L. [US/US]; (US) (For US Only).
HODGETTS, Kevin, J. [GB/US]; (US) (For US Only)
Inventors: CALDWELL, Timothy, M.; (US).
CHENARD, Bertrand, L.; (US).
HODGETTS, Kevin, J.; (US)
Agent: ALEXANDER, John, B.; Edwards Angell Palmer & Dodge LLP, P.O. Box 55874, Boston, MA 02205 (US)
Priority Data:
60/647,190 25.01.2005 US
Title (EN) SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES
(FR) ANALOGUES DE PYRIDAZINYL-ET DE PYRIMIDINYL-QUINOLIN-4-YLAMINE SUBSTITUES
Abstract: front page image
(EN)Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
(FR)L'invention concerne des analogues de pyridazinyl- et de pyrimidinyl-quinolin-4-ylamine substitués. Lesdits composés sont des ligands qui peuvent être utilisés afin de moduler l'activité de récepteurs spécifiques in vivo ou in vitro, et sont particulièrement utiles dans le traitement d'états associés à l'activation pathologique de récepteurs chez les humains, les animaux de compagnie et les animaux d'élevage. L'invention concerne également des compositions pharmaceutiques et des méthodes d'utilisation de ces dernières pour traiter lesdits troubles, ainsi que des méthodes d'utilisation desdits ligands pour des études de localisation de récepteurs.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)